M.D. Anderson Cancer Center: Leukemia trials

The registry lists 302 Leukemia studies with M.D. Anderson Cancer Center as lead sponsor. 5 are open to participants now and 169 have results posted.

Early Phase 1 1Phase 1 121Phase 2 201Phase 3 13No phase 26(a study in two phases counts in both)

Studies

Page 3 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02652871Phase 1
• Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02649764Phase 1
• Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic SyndromeActive, not recruitingNCT02530463Phase 2
• CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesCompletedNCT02529813Phase 1
• Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsWithdrawnNCT02420938Phase 2
• Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk DiseaseCompletedNCT02378701
• Cord Blood Natural Killer (NK) Cells in Leukemia/LymphomaCompletedNCT02280525Phase 1
• Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
• An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)TerminatedNCT02225574Phase 1
• Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT02194374Phase 1
• Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)TerminatedNCT02141477Phase 1
• Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell TransplantCompletedNCT02083250Phase 1
• IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)WithdrawnNCT02028039Phase 2
• A Feasibility Study of Prophylactic White Blood Cell TransfusionsCompletedNCT01932710Phase 2
• Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT01891981Phase 1
• Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01787474Phase 1
• Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTerminatedNCT01751425Phase 1
• CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)CompletedNCT01653717Phase 1
• Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)WithdrawnNCT01649622Phase 2
• Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeTerminatedNCT01636609Phase 1
• NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
• Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant SurvivorsActive, not recruitingNCT01608152
• Ultrafiltration (Aquapheresis) in Patients With Leukemia and Severe Fluid OverloadWithdrawnNCT01508260Not applicable
• Infusion of Allogeneic CD19-Specific T Cells From Peripheral BloodCompletedNCT01497184Phase 1
• Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic MalignanciesCompletedNCT01471067Phase 1
• Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)CompletedNCT01460498Phase 1
• Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)Active, not recruitingNCT01446133Phase 2
• Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced LeukemiasCompletedNCT01396499Phase 1
• Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT01372540Phase 1
• Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T CellsCompletedNCT01362452Phase 1
• 4'-Thio-araC (Thiarabine) in Advanced Hematologic MalignanciesCompletedNCT01139151Phase 1
• Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With MalignanciesWithdrawnNCT01101412Phase 1/2
• Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid MalignanciesCompletedNCT01094860Phase 1
• Late Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT01092741Phase 2
• Symptom Burden in Chronic Myeloid Leukemia (CML)Status unknownNCT01046305
• Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic SyndromesTerminatedNCT01029509Phase 1
• Autologous Transplantation for Chronic Myelogenous LeukemiaCompletedNCT01003054Phase 2
• Infusion of Expanded Cord Blood T CellsWithdrawnNCT00972101Phase 1
• Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic LeukemiaWithdrawnNCT00962715Phase 1/2
• Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 MutationsCompletedNCT00943943Phase 1
• FTS Study in Patients With Advanced Hematologic MalignanciesCompletedNCT00867230Phase 1
• PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic TransplantationWithdrawnNCT00866346Phase 1
• Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT00800566Phase 1
• 8-Chloro-Adenosine in Chronic Lymphocytic LeukemiaCompletedNCT00714103Phase 1
• Oral Valganciclovir Versus ValacyclovirCompletedNCT00562770Phase 2
• Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)Active, not recruitingNCT00525746
• Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell VaccinesTerminatedNCT00514189Phase 1
• Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome PatientsCompletedNCT00504920
• Genetic Study of Chronic Lymphocytic Leukemia FamiliesStatus unknownNCT00503256
• Molecular Epidemiology of Acute Myelogenous LeukemiaStatus unknownNCT00502983
• Exercise Program for Adolescents and Young Adults With CancerCompletedNCT00502749Not applicable
• Cord Blood Expansion on Mesenchymal Stem CellsCompletedNCT00498316Phase 1
• Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)CompletedNCT00493129Phase 2
• Children's Resiliency, Adjustment, and CopingCompletedNCT00489632
• Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid MalignanciesTerminatedNCT00473551Phase 1
• Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT00459524
• Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic SyndromesCompletedNCT00451997Phase 2
• Autologous Stem Cell Transplants for Chronic Myelogenous LeukemiaWithdrawnNCT00446173Phase 2
• Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid MalignanciesCompletedNCT00410982Phase 1
• Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00402558Phase 1
• Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia PatientsCompletedNCT00386373Not applicable
• Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell TransplantationCompletedNCT00383994Phase 1
• Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLSCompletedNCT00360438Phase 1/2
• Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)CompletedNCT00350818Phase 1
• A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)CompletedNCT00349596Phase 1
• PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CMLCompletedNCT00303290Phase 1
• Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic LeukemiaCompletedNCT00102661Phase 2
• PTK 787 and Gleevec in Patients With AML, AMM, and CML-BPCompletedNCT00088231Phase 1/2
• Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic LeukemiaTerminatedNCT00081887Phase 1
• RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell LymphomaCompletedNCT00081874Phase 1/2
• Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00075010Phase 1/2
• Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous PlateletsTerminatedNCT00074763Phase 3
• Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)TerminatedNCT00074750Phase 1
• Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT00065143Phase 2
• High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)CompletedNCT00050531Phase 3
• Therapy of Early Chronic Phase CML With GleevecCompletedNCT00048672Phase 2
• Anti-Leukemic Dendritic Cell Activated Donor LymphocytesTerminatedNCT00048100Phase 1
• Study of Lonafarnib and Gleevec in Chronic Myelogenous LeukemiaCompletedNCT00047502Phase 1
• Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00040105Phase 1
• Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid MalignanciesTerminatedNCT00038883Not applicable
• Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated LymphocytesWithdrawnNCT00038870Not applicable
• Safety and Efficacy of Campath in Nonmyeloablative TransplantationCompletedNCT00038844Not applicable
• Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDSCompletedNCT00038831Phase 1/2
• CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell TransplantationTerminatedNCT00038818Not applicable
• Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)TerminatedNCT00038805Phase 2/3
• Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure StatesTerminatedNCT00038779Not applicable
• Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)CompletedNCT00038597Phase 2
• A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic ApproachTerminatedNCT00038415Phase 1/2
• PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or IntronTerminatedNCT00037882Phase 2
• Clofarabine in Chronic Lymphocytic LeukemiaCompletedNCT00028418Phase 1
• Bortezomib in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00023881Phase 2
• Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous TreatmentWithdrawnNCT00006091Phase 2
• Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic LeukemiaWithdrawnNCT00006090Phase 2
• Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00005092Phase 1
• Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00004263Phase 1
• Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT00003693Phase 1
• Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00003239Phase 2
• Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00002844Phase 2
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic LeukemiaCompletedNCT00002838Phase 1/2
• Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous LeukemiaCompletedNCT00002833Phase 2